Site-directed modification of FVIII

Details for Australian Patent Application No. 2012203813 (hide)

Owner Bayer HealthCare LLC

Inventors Pan, Clark Q.; Chen, Jianmin; Murphy, John E.; Mei, Baisong; Tang, Liang; Strauss, Jonathan S.; Wang, Deqian; Tjandra, Hendri; Barnett, Thomas

Agent Davies Collison Cave

Pub. Number AU-A-2012203813

Parent 2005304622

Filing date 28 June 2012

Wipo publication date 19 July 2012

International Classifications

C07K 14/755 Peptides having more than 20 amino acids

C07H 21/04 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12P 21/06 Preparation of peptides or proteins - produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Event Publications

12 July 2012 Complete Application Filed

19 July 2012 Application Open to Public Inspection

  Published as AU-A-2012203813

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012203814-Herbicidal suspension

2012203812-Erythropoietin receptor peptide formulations and uses